Scientists Not Paying Enough Attention to Regulatory Issues, Pep Talk Presenter Warns | GenomeWeb
SAN DIEGO — Researchers developing protein therapeutics need to pay better attention to regulatory issues, especially to changes in the way the US Food and Drug Administration reviews new product applications, according to a presentation at Cambridge Healthtech Institute’s Pep Talk meeting, held here this week.
While most of the sessions focused on the science of protein research, one session homed in on regulatory issues surrounding the development of new protein therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.